瑞士HIV阳性与阴性者亚临床冠心病的比较研究
该研究利用冠脉钙化评分和冠脉CT血管造影,比较428例HIV阳性者与276例因临床指征转诊的HIV阴性者的亚临床动脉粥样硬化。两组Framingham风险评分相似,非钙化/混合斑块和高危斑块患病率相近,但HIV阳性者钙化斑块患病率及冠脉受累严重程度评分更低,晚期免疫抑制与非钙化/混合斑块相关。
要点
- HIV阳性者非钙化/混合斑块和高危斑块患病率与Framingham风险相似的HIV阴性者相当。
- HIV阳性者钙化斑块患病率及冠脉受累严重程度评分低于HIV阴性者。
- 晚期免疫抑制与HIV阳性者非钙化/混合斑块独立相关。
核心结论
- 瑞士HIV阳性者非钙化/混合斑块和高危斑块程度与Framingham风险相似的HIV阴性者相当,但钙化斑块、冠脉受累范围和严重程度评分可能更低。
研究设计与样本
- 研究纳入428例瑞士HIV队列研究的HIV阳性者和276例因临床指征同时转诊行冠脉CT血管造影的HIV阴性对照。
- 采用冠脉钙化评分和冠脉CT血管造影评估亚临床动脉粥样硬化。
- 通过单变量和多变量分析评估HIV感染、心血管风险谱及HIV相关因素与亚临床动脉粥样硬化的关联。
主要发现
- HIV阳性者中位HIV感染病程15年,中位年龄52岁,低于HIV阴性者的56岁(P < 0.01)。
- 两组中位10年Framingham风险评分相似(9.0% vs. 9.7%;P = 0.40)。
- 冠脉钙化评分>0的患病率(53% vs. 56.2%;P = 0.42)和中位冠脉钙化评分(47 vs. 47;P = 0.80)相似。
- 多变量校正后,HIV阳性者钙化斑块患病率低于HIV阴性者(36.9% vs. 48.6%,P < 0.01;aOR 0.57;95%CI 0.40-0.82;P < 0.01)。
- 晚期免疫抑制与非钙化/混合斑块相关(aOR 1.97;95%CI 1.09-3.56;P = 0.02)。
临床怎么用
- 对于Framingham风险相似的HIV阳性者,应关注非钙化/混合斑块和高危斑块,而非仅依赖钙化评分评估风险。
- HIV阳性者钙化斑块负荷可能较低,解读冠脉钙化评分时需结合HIV感染和免疫抑制状态。
- 晚期免疫抑制的HIV阳性者可能需更积极评估非钙化/混合斑块。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: HIV-positive persons have increased cardiovascular event rates but data on the prevalence of subclinical atherosclerosis compared with HIV-negative persons are not uniform. We assessed subclinical atherosclerosis utilizing coronary artery calcium (CAC) scoring and coronary computed tomography angiography (CCTA) in 428 HIV-positive participants of the Swiss HIV Cohort Study and 276 HIV-negative controls concurrently referred for clinically indicated CCTA. METHODS AND RESULTS: We assessed the association of HIV infection, cardiovascular risk profile, and HIV-related factors with subclinical atherosclerosis in univariable and multivariable analyses. HIV-positive participants (median duration of HIV infection, 15 years) were younger than HIV-negative participants (median age 52 vs. 56 years; P < 0.01) but had similar median 10-year Framingham risk scores (9.0% vs. 9.7%; P = 0.40). The prevalence of CAC score >0 (53% vs. 56.2%; P = 0.42) and median CAC scores (47 vs. 47; P = 0.80) were similar, as was the prevalence of any, non-calcified/mixed, and high-risk plaque. In multivariable adjusted analysis, HIV-positive participants had a lower prevalence of calcified plaque than HIV-negative participants [36.9% vs. 48.6%, P < 0.01; adjusted odds ratio (aOR) 0.57; 95% confidence interval (CI) 0.40-0.82; P < 0.01], lower coronary segment severity score (aOR 0.72; 95% CI 0.53-0.99; P = 0.04), and lower segment involvement score (aOR 0.71, 95% CI 0.52-0.97; P = 0.03). Advanced immunosuppression was associated with non-calcified/mixed plaque (aOR 1.97; 95% CI 1.09-3.56; P = 0.02). CONCLUSION: HIV-positive persons in Switzerland had a similar degree of non-calcified/mixed plaque and high-risk plaque, and may have less calcified coronary plaque, and lower coronary atherosclerosis involvement and severity scores than HIV-negative persons with similar Framingham risk scores.
引用
- Tarr PE, Ledergerber B, Calmy A, et al. Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons. Eur Heart J. 2018. PMID: 29590332. doi:10.1093/eurheartj/ehy163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。